Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
Stafford S, Bech P, Fridhammar A, Miresashvili N, Nilsson A, Willis M, Liu A
Read more and download the article
Applied Health Economics and Health Policy 2022;20(4):543–555
DOI: https://doi.org/10.1007/s40258-022-00726-z
